ALHC at a glance
Alignment Healthcare, Inc. (ALHC, SEC CIK 1832466) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alignment Healthcare, Inc. (ALHC) reported revenue of $3.9 billion (up 46.1% from FY2024) and a net loss of $724,000. Diluted EPS was $0.00.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Alignment Healthcare, Inc. (ALHC) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KONOWIECKI JOSEPH S on September 17, 2026 of 23,511 shares at $8.61 per share.
- In the last 90 days, ALHC insiders reported 0 open-market purchases ($0) and 10 open-market sales ($23.1M) on Form 4, a net sale of $23.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.9B
- +46.1% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$23.1M
- 13F holders
- 33 funds
- $2.6B · +0 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Consumer-centric Medicare Advantage plans focused on coordinated, proactive care for seniors using integrated clinical and technology platform
- Emphasized this year: Expanded "Care Anywhere" in-house clinician-driven care model providing free, personalized at-home and virtual chronic condition management
- Strategic shift: Greater investment in internal clinical staff (450 FTEs, 25% workforce) to reduce hospitalizations and improve outcomes via direct care delivery
- Quantitative growth: Health Plan Membership reached 236,300 at 30% CAGR since inception with revenue 5-year CAGR of 36% through 2025
- Noteworthy fact: Proprietary AVA platform integrates data from 200+ sources using AI for real-time, prescriptive care insights enhancing member and provider workflows
Risk Factors
- Regulatory risk: potential loss/suspension of CMS Medicare Advantage contracts affecting revenue source
- Macroeconomic threat: geographic concentration in few U.S. states limits expansion, increasing exposure to regional market downturns
- Operational vulnerability: dependency on AVA AI platform for clinical initiatives poses risk of regulatory and operational setbacks
- Competitive risk: competition for physician networks intensifies due to healthcare industry consolidation with better-resourced plans
- Financial risk: accumulated deficit $1,009.0 million as of 12/31/2025 with net loss $1.0 million in 2025, $128.1 million in 2024
Management Discussion & Analysis
- Revenue $3.949B, up 46.1% YoY; earned premiums $3.912B, +46.4% driven by 25% membership growth to 236,300 and higher PMPM rates
- Operating income $14.8M vs loss $101.6M; operating margin 0.4% vs (3.7)% in prior year
- Medical expenses segment largest, 87.6% of revenue vs 89.0%, MBR improved to 87.5% from 88.8%
- Adjusted EBITDA $109.9M vs $1.3M; adjusted gross profit $494.8M, up 63.5%
- Management outlook: focus on expanding membership (275,300 Health Plan Members as of Jan 1, 2026), new market entry, investing in AVA platform, strong CMS star ratings support financial incentives and sustainable growth
AI summary of the ALHC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to Annual Report risk factors disclosed for quarter ended June 30, 2026
- Regulatory compliance risk carried forward without quarterly updates
- Operational and competitive risks unchanged from the most recent 10-K
- Financial liquidity, debt maturity, currency, and concentration risks unchanged from the most recent 10-K
AI summary of the ALHC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued July 30, 2026 and furnished as Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual meeting held June 4, 2026, with 194,112,992 shares represented
- All three Class II directors elected to three-year terms through the 2029 annual meeting
Item 7.01: Regulation FD Disclosure
- Executive leadership structure changes announced May 12, 2026
- Leadership transition may affect strategic execution and investor confidence
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Board-approved bylaw amendment effective May 6, 2026
- New Vice Chair position added to Board leadership structure
AI summaries of ALHC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALHC
Don't miss the next ALHC filing
- Alerts as it files. A push when ALHC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALHC, by share count.
- Ask anything. An AI agent that reads every ALHC filing and answers with sources.
ALHC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| KONOWIECKI JOSEPH S | Sell | Sep 17, 2026 | 23,511 | $8.61 |
| KAO JOHN E | Sell | Sep 14, 2026 | 27,400 | $13.00 |
| KAO JOHN E | Sell | Sep 11, 2026 | 385,270 | $12.68 |
| Maroney Dawn Christine | Sell | Sep 11, 2026 | 122,707 | $12.68 |
| KAO JOHN E | Sell | Sep 10, 2026 | 172,600 | $12.96 |
| Maroney Dawn Christine | Sell | Aug 14, 2026 | 5,000 | $14.00 |
| KAO JOHN E | Sell | Aug 10, 2026 | 298,000 | $13.88 |
| Maroney Dawn Christine | M | Jul 15, 2026 | 152,068 | $9.06 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.7B | $3.9B |
| Operating Income | - | -$101.6M | $14.8M |
| Net Income | -$148.0M | -$128.0M | -$724K |
| Op. Margin | - | -3.8% | 0.4% |
| Net Margin | - | -4.7% | -0.0% |
| Balance Sheet | |||
| Total Assets | $591.9M | $782.1M | $1.1B |
| Equity | - | $99.9M | $179.3M |
| ROE | - | -128.2% | -0.4% |
| Per Share | |||
| EPS | $-0.79 | $-0.67 | $0.00 |
| Cash Flow | |||
| Operating CF | -$59.2M | $34.8M | $139.9M |
| CapEx | - | $41.4M | $26.8M |
Source: XBRL data in Alignment Healthcare, Inc. (ALHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALHC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $2.57B |
| Q1 2026 | 33 | $1.64B |
| Q4 2025 | 27 | $1.61B |
| Q3 2025 | 28 | $1.33B |
| Q2 2025 | 26 | $990.8M |
| Q1 2025 | 23 | $760.0M |
| Q4 2024 | 19 | $459.1M |
| Q3 2024 | 13 | $78.5M |
- Bank of America Corp+6.13M (+191%)
- BlackRock+5.27M (+37%)
- Invesco Ltd+3.37M (+48%)
- State Street Corp+3.00M (+70%)
- Goldman Sachs Group+3.00M (+297%)
- Millennium Management−2.38M (-62%)
- FMR LLC (Fidelity)−1.97M (-12%)
- Renaissance Technologies LLC−1.90M (-66%)
- T. Rowe Price Group−802.2K (-14%)
- AQR Capital Management−223.5K (-27%)
- Citizens Financial Group+33.3K
- Allstate+15.7K
- Citadel Advisors LLC−5.36M
- Marex Group plc−34.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALHC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 4 | Aug 10, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 13, 2026 | - | - |
Related Health Care companies
- CNC · Centene CorporationHospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DEHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
ALHC SEC filings: frequently asked questions
Are ALHC insiders buying or selling?
In the last 90 days, Alignment Healthcare, Inc. (ALHC) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $23.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALHC stock?
As of June 30, 2026, the largest Alignment Healthcare, Inc. (ALHC) holders among the 13F filers tracked by SignalX were BlackRock ($460.6 million), FMR LLC (Fidelity) ($331.5 million), Vanguard Portfolio Management LLC ($277.9 million), Invesco Ltd ($246.8 million), Bank of America Corp ($222.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALHC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alignment Healthcare, Inc. (ALHC) reported revenue of $3.9 billion (up 46.1% from FY2024) and a net loss of $724,000. Diluted EPS was $0.00. The figures come from the XBRL data in the 10-K.
What are the main risks in ALHC's latest 10-K?
In the 10-K filed February 27, 2026, Alignment Healthcare, Inc. (ALHC) flagged: Regulatory risk: potential loss/suspension of CMS Medicare Advantage contracts affecting revenue source. Macroeconomic threat: geographic concentration in few U.S. states limits expansion, increasing exposure to regional market downturns. (AI summary of the Risk Factors section.)
What did ALHC report in its latest 8-K?
Alignment Healthcare, Inc. (ALHC) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results covered quarter ended June 30, 2026.
What are the latest ALHC SEC filings?
Alignment Healthcare, Inc. (ALHC) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on September 18, 2026.
What is ALHC's SEC CIK number?
Alignment Healthcare, Inc. (ALHC)'s SEC Central Index Key (CIK) is 1832466. EDGAR lists every ALHC filing under that number.
Ask anything about ALHC
The research agent reads ALHC's filings, financials, insider trades and 13F holders, then answers with sources.